Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Contraceptive Postmarketing Studies To Be Discussed By FDA Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency seeks advice on how to get better information on safety and efficacy of hormonal contraceptives.

You may also be interested in...

User Fees Would Fund Safety Oversight Throughout Product Life Cycles

PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.

Patient-Reported Outcomes Data Can Be Used In Labeling, FDA Draft Guidance Says

Document outlines the evaluation and development of appropriate PRO instruments to collect outcomes data that supports labeling claims.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts